Safety, immunogenicity, and induction of immunologic memory by a serogroupC meningococcal conjugate vaccine in infants - A randomized controlled trial

Context Neisseria meningitidis is a common cause of meningitis' and septice mia in infants worldwide. Whether a meningococcal C conjugate vaccine prote cts infants against the serogroup C strain is unknown. Objectives To determine whether a meningococcal C conjugate vaccine is safe and immunogenic and induces immunologic memory in infants. Design Single-center, double-blind, randomized controlled trial in 1995 and 1996. Setting Community, Oxfordshire, England. Participants One hundred eighty-two healthy infants. Interventions Participants were randomly assigned to receive vaccination wi th 0.5-mL doses of 1 of 2 lots of meningococcal C conjugate Vaccine (groups 1 and 2; n=60 in each group) or a hepatitis B control vaccine (group 3; n= 62), administered with routine immunizations at 2, 3, and 4 months of age. Approximately half of each group received meningococcal C conjugate vaccine and half received plain meningococcal polysaccharide Vaccine (MPS) at 12 m onths of age. Main Outcome Measures Serum antibodies to meningococcal C polysaccharide, a ssayed by enzyme-linked immunosorbent assay, and serum bactericidal activit y (SBA), at 2, 3, 4, 5, 12, and 13 months of age; local and systemic reacti ons, recorded for 6 days after each vaccination, compared by intervention g roup. Results Meningococcal C conjugate vaccine was well tolerated. After 3 doses , children in groups 1 and 2 achieved significantly higher meningococcal C IgG geometric mean concentrations (2 2 and 17 U/mL, respectively, vs 0.20 U /mL; P<.001) and SEA titers (629 and 420, respectively, vs 4.1; P<.001) tha n controls. At 12 months, antibody concentrations had decreased in all grou ps but remained significantly higher in children vaccinated with meningococ cal C conjugate vaccine (SBA, 24 and 16 in groups 1 and 2, respectively, vs 4.2 in group 3; P<.001). Following vaccination with MPS at 12 months of ag e, SEA in the meningococcal C conjugate vaccine group was significantly hig her than in controls (SBA, 789 vs 4.5; P<.001). Conclusions Our data indicate that meningococcal C conjugate vaccine is saf e and immunogenic and results in immunologic memory when given with other r outinely administered vaccines to infants at 2, 3, and 4 months of age.